MDCO: Medicines Company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MDCO: Medicines Company

MDCO 84.90

0.0%

Jan 6 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Rich1 who wrote (70)	4/29/2003 11:15:25 PM
From: Mike	Read Replies (1) of 125

JNJ stent and MDCO have no direct business relationship. Angiomax has a story to tell about cost saving analysis from the Replace II trial. This trial showed a cost savings of approx $400 using Angiomax over heparin and 2b/3a's. In addition,there was a $180 decrease in hospital charges due to the lower bleeding complications with the use of Angiomax. These cost savings data is going to play much better with the Cypher stent out. The Cypher stent from JNJ is approx $3100 vs approx $1200 for a standard non coated stent. With 1.5 stents used on the average patient the hospital has the potential for great lose of profit with the use of Cypher stent. Angiomax useage could recover some of that lose in revenue. Mike

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next